Barbara W. Chwirot

Barbara W. Chwirot

Auto-generated profile, based on publicly available information

Barbara W. Chwirot

Department of Medical Biology, Faculty of Biology and Environment Protection, Nicolaus Copernicus University, Toruń, Poland

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2016 in Melanoma Research
Verified
Journal Article
Closed access
ŁKŁukasz Kuźbicki
Łukasz Kuźbicki
DLDariusz Lange
Dariusz Lange
ASAgata Stanek-Widera
Agata Stanek-Widera
BCBarbara W. Chwirot
Barbara W. Chwirot
Because of the well-known heterogeneity of melanomas, prognosis of the disease is often difficult to assess even for lesions classified in similar stages. The aim of this study was to assess the usefulness of COX-2 as a melanoma prognostic marker and to establish an optimum algorithm for analysis of COX-2 expression levels in lesions of interest. Expression of COX-2 was detected immunohistochemically in standard sections of formalin-fixed paraffin-embedded tissue samples of 85 primary melanomas, 36 lymph node metastases, and five skin metastases including 39 cases of paired primary and metastatic lesions obtained from the same patient. Enhanced expression of COX-2 in primary melanomas is an indicator of poorer prognosis. A significant correlation was found between high expression of COX-2 in primary lesions and shorter survival. The enhancement of COX-2 expression is also positively correlated with other prognostic factors such as tumor thickness and infiltration level, ulceration, high mitotic index, more invasive histologic type, vertical growth phase, and lymph node metastasis. On the whole, the results suggest that intratumoral expression of COX-2 is a strong negative prognostic marker for patients with melanoma. Moreover, our work shows that a simple and objective immunohistochemical scoring algorithm involving the determination of only a percentage fraction of positively stained cells is sufficient to obtain the prognostic information.

15 December 2017 in BMC Cancer
Verified
Journal Article
Open access
PDF file
ŁKŁukasz Kuźbicki
Łukasz Kuźbicki
DLDariusz Lange
Dariusz Lange
ASAgata Stanek-Widera
Agata Stanek-Widera
BCBarbara W. Chwirot
Barbara W. Chwirot
Histone demethylase JARID1B plays several context dependent roles in epigenetic regulation of cellular differentiation in normal development and is highly expressed in multiple human cancers. The protein is a strong transcriptional repressor capable of downregulating numerous genes. There are three splicing isoforms of JARID1B, however the links between the protein structure and function are not clear. The expression pattern of JARID1B in human melanoma seems to be different from observed in other cancers. Moreover, up to now no data on the impact of JARID1B expression in cutaneous melanoma on the patients’ prognosis have been reported. We investigated immunohistochemically the association of intratumoral expression of total JARID1B protein and its RBP2-H1 isoform in primary and metastatic melanomas with prognosis for the patients. Expression of both total JARID1B protein and its RBP2-H1 variant was found in all the melanomas investigated. Our results indicate, however, that only high (above 90% of the cells) intratumoral expression of RBP2-H1 can be considered prognostic factor associated with worse overall survival of the patients. Such results if considered together with data demonstrating a switch to enhanced expression of RBP2-H1 at early stages of malignant transformation of melanocytes are in agreement with hypothetical crucial role of JARID1B in the course of melanoma development and progression and suggest that altered splicing of JARID1B may be important factor increasing melanoma aggressiveness.

3 April 2018 in Oncotarget
Verified
Journal Article
Open access
PDF file
ŁKŁukasz Kuźbicki
Łukasz Kuźbicki
DLDariusz Lange
Dariusz Lange
ASAgata Stanek-Widera
Agata Stanek-Widera
AGAgnieszka Glińska
Agnieszka Glińska
BCBarbara W. Chwirot
Barbara W. Chwirot
Enhanced intratumoral expression of RNF2 is a favorable prognostic factor for patients with cutaneous melanoma? Enhanced intratumoral expression of RNF2 is a favorable prognostic factor for patients with cutaneous melanoma?